Bartlett & CO. Wealth Management LLC Cuts Stake in Johnson & Johnson $JNJ

Key Points

• Bartlett & CO. Wealth Management LLC cut its Johnson & Johnson stake by 4.7% in Q4, selling 11,849 shares and finishing the quarter with 242,668 shares valued at $50.22 million.
• Several large institutions materially increased positions—Capital International (+545.6% to ~3.87M shares), Amundi (13.35M shares), Marshall Wace and Wellington—leaving hedge funds and institutions owning about 69.55% of J&J.
• J&J reported Q4 EPS of $2.46 on $24.28 billion in revenue, and analysts are largely positive (Citigroup raised its price target to $285; MarketBeat average PT $238.17), though the imminent Q1 print and guidance represent the main near-term catalyst and risk.

Bartlett & CO. Wealth Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.7% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 242,668 shares of the company's stock after selling 11,849 shares during the quarter. Bartlett & CO. Wealth Management LLC's holdings in Johnson & Johnson were worth $50,220,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Capital International Investors lifted its stake in Johnson & Johnson by 545.6% in the third quarter. Capital International Investors now owns 3,865,050 shares of the company's stock valued at $716,657,000 after purchasing an additional 3,266,354 shares during the last quarter. Amundi lifted its stake in Johnson & Johnson by 19.3% in the third quarter. Amundi now owns 13,354,936 shares of the company's stock valued at $2,512,719,000 after purchasing an additional 2,163,838 shares during the last quarter. Marshall Wace LLP lifted its stake in Johnson & Johnson by 126.3% in the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company's stock valued at $664,575,000 after purchasing an additional 2,000,609 shares during the last quarter. Danske Bank A S purchased a new position in Johnson & Johnson in the third quarter valued at approximately $367,467,000. Finally, Wellington Management Group LLP lifted its stake in Johnson & Johnson by 3.8% in the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock valued at $4,789,914,000 after purchasing an additional 956,239 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $238.00 on Tuesday. The business has a fifty day moving average price of $241.44 and a 200-day moving average price of $215.95. Johnson & Johnson has a one year low of $146.12 and a one year high of $251.71. The firm has a market capitalization of $573.25 billion, a P/E ratio of 21.54, a PEG ratio of 2.38 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion for the quarter. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Transactions at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. This trade represents a 4.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 30,142 shares of company stock worth $7,360,528. Insiders own 0.16% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on JNJ. Citigroup upped their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a research note on Tuesday, April 7th. Bank of America reaffirmed a "neutral" rating on shares of Johnson & Johnson in a report on Monday, March 2nd. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Barclays upped their price objective on shares of Johnson & Johnson from $217.00 to $234.00 and gave the company an "equal weight" rating in a report on Thursday, March 19th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $238.17.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst price-target increase — J&J had a price-target raise to $267, a near-term bullish signal that can support the stock if earnings and guidance align. Article Title
• Positive Sentiment: Strong Innovative Medicines growth noted by investors/letters — Institutional commentary highlights J&J’s Innovative Medicines momentum as a core growth driver underpinning YTD gains and medium-term earnings resilience. Article Title
• Positive Sentiment: TECNIS PureSee IOL clinical/real-world data spotlight — New data presented at ASCRS highlight adoption potential for J&J’s recently FDA-approved intraocular lens, supporting the company’s ophthalmology growth narrative. Article Title
• Positive Sentiment: Steady index momentum — J&J is being noted for steady momentum within the Russell 1000, which can attract passive/index flows and support valuation. Article Title
• Neutral Sentiment: Q1 preview and analyst expectations — Multiple previews (Seeking Alpha, TipRanks) emphasize tomorrow’s Q1 print and guidance as the main near-term catalyst; analysts expect continued earnings but will watch revenue mix and guidance closely. Article Title Article Title
• Neutral Sentiment: Market backdrop — A broader tech-led rally (Nasdaq) and weekly earnings calendar may lift sentiment for large-cap cyclicals, but J&J’s move will hinge more on its own results than tape action. Article Title Article Title
• Negative Sentiment: Short-term pullback and volatility risk — Recent headlines note a 1.2% pullback and intraday weakness; with Q1 due imminently, any guidance miss or cautious commentary could push shares lower. Article Title
• Negative Sentiment: Comparative pressures from higher-growth peers — Coverage comparing J&J to faster-growth names (e.g., Lilly) frames a valuation-growth tradeoff that could limit upside if investors favor high-growth pharma exposure. Article Title

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.